Skip to main content
SpringerLink
Log in

The EU/US Task Force’s Future for Anti-Amyloid Trials: Faites Vos Jeux

  • Commentary
  • Published:
The Journal of Prevention of Alzheimer's Disease Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine. 2016;8(6):595–608.

    Article  CAS  Google Scholar 

  2. Golde TE, Schneider LS, Koo EH. Anti-Aβ Therapeutics in Alzheimer’s Disease: The Need for a Paradigm Shift. Neuron. 2011;69(2):203–13.

    Article  CAS  Google Scholar 

  3. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266(1):93–8.

    Article  CAS  Google Scholar 

  4. Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease. New England Journal of Medicine. 2018;378(4):321–30.

    Article  CAS  Google Scholar 

  5. Ioannidis JPA. The Proposal to Lower P Value Thresholds to.005. JAMA. 2018;319(14):1429–30.

    Article  Google Scholar 

  6. Wood J, Freemantle N, King M, Nazareth I. Trap of trends to statistical significance: likelihood of near significant P value becoming more significant with extra data. BMJ: British Medical Journal. 2014;348:g2215.

    Article  Google Scholar 

  7. FDA. Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Guidance for Industry (Draft Guidance) 2019 [Draft guidance]. Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs.

Download references

Author information

Authors and Affiliations

  1. Keck School of Medicine of USC, Los Angeles, California, USA, 90033

    Lon S. Schneider

Authors
  1. Lon S. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lon S. Schneider.

Ethics declarations

Conflict of interest: Dr. Schneider reports grants and personal fees from Eli Lilly, personal fees from Avraham, Ltd, personal fees from Boehringer Ingelheim, grants and personal fees from Merck, personal fees from Neurim, Ltd, personal fees from Neuronix, Ltd, personal fees from Cognition, personal fees from Eisai, personal fees from Takeda, personal fees from vTv, grants and personal fees from Roche / Genentech, grants from Biogen, grants from Novartis, personal fees from Abbott, grants from Biohaven, grants from Washington Univ/NIA DIAN-TU, personal fees from Samus, outside the submitted work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schneider, L.S. The EU/US Task Force’s Future for Anti-Amyloid Trials: Faites Vos Jeux. J Prev Alzheimers Dis 7, 199–200 (2020). https://doi.org/10.14283/jpad.2020.29

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.14283/jpad.2020.29

Search

Navigation